Anti-Microbial Savior BioteQ Co., Ltd.(TW:6864)
NT$36.70-1.10 (-2.91%)
TW:6864
Anti-Microbial Savior BioteQ Co., Ltd. financials statements
NT$36.70
At close:-1.10 (-2.91%)
Anti-Microbial Savior BioteQ Co., Ltd. (6864) Ratios
Anti-Microbial Savior BioteQ Co., Ltd. Ratios
TW:6864's free cash flow for Q2 2026 was NT$-58.75M. For the 2026 fiscal year, TW:6864's free cash flow was decreased by NT$-13.74M and operating cash flow was NT$-45.01M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 47.84 | 19.01 | 11.94 | 15.94 | 31.39 |
| Quick Ratio | 47.67 | 18.80 | 11.87 | 15.91 | 31.24 |
| Cash Ratio | 47.01 | 18.19 | 11.21 | 15.64 | 30.95 |
| Solvency Ratio | -8.32 | -5.86 | -5.90 | -2.27 | -0.86 |
| Operating Cash Flow Ratio | -7.84 | -6.01 | -6.90 | -3.66 | -3.74 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -24.16 |
| Net Current Asset Value | NT$ 464.49M | NT$ 192.00M | NT$ 76.50M | NT$ 123.92M | NT$ 151.77M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.01 | 0.02 | 0.06 |
| Debt-to-Equity Ratio | 0.00 | 0.01 | 0.01 | 0.02 | 0.07 |
| Debt-to-Capital Ratio | 0.00 | 0.01 | 0.01 | 0.02 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Financial Leverage Ratio | 1.02 | 1.05 | 1.06 | 1.06 | 1.08 |
| Debt Service Coverage Ratio | -4040.57 | -1989.66 | -981.79 | -269.56 | -15.90 |
| Interest Coverage Ratio | -4570.71 | -2389.91 | -1426.33 | -528.91 | -318.03 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest Debt Per Share | 0.04 | 0.08 | 0.06 | 0.16 | 0.75 |
| Net Debt to EBITDA | 5.48 | 3.01 | 1.67 | 4.21 | 7.77 |
| Profitability Margins | |||||
| Gross Profit Margin | -1530.74% | 23.53% | -1397.80% | 47.91% | 53.41% |
| EBIT Margin | -13595.61% | -12170.75% | -7795.19% | -1472.93% | -30928.41% |
| EBITDA Margin | -12018.70% | -10403.43% | -6352.20% | -1118.80% | -22292.05% |
| Operating Profit Margin | -13595.61% | -12496.24% | -8228.85% | -1608.12% | -32164.77% |
| Pretax Profit Margin | -13257.37% | -12175.98% | -7800.96% | -1475.97% | -31029.55% |
| Net Profit Margin | -13257.37% | -12175.98% | -7112.91% | -1176.75% | -25398.86% |
| Continuous Operations Profit Margin | -13257.37% | -12175.98% | -7112.91% | -1176.75% | -25398.86% |
| Net Income Per EBT | 100.00% | 100.00% | 91.18% | 79.73% | 81.85% |
| EBT Per EBIT | 97.51% | 97.44% | 94.80% | 91.78% | 96.47% |
| Return on Assets (ROA) | -17.99% | -30.03% | -40.44% | -17.44% | -10.11% |
| Return on Equity (ROE) | -18.33% | -31.40% | -42.78% | -18.43% | -10.96% |
| Return on Capital Employed (ROCE) | -18.80% | -32.20% | -49.49% | -24.99% | -13.12% |
| Return on Invested Capital (ROIC) | -18.76% | -31.91% | -44.61% | -19.63% | -10.62% |
| Return on Tangible Assets | -17.99% | -30.03% | -40.44% | -17.44% | -10.11% |
| Earnings Yield | -3.34% | -4.03% | -8.22% | -4.18% | -2.14% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.16 | 1.13 | 1.71 | 27.80 | 1.29 |
| Payables Turnover | 0.00 | 0.00 | 40.39 | 5.20 | 0.04 |
| Inventory Turnover | 6.98 | 0.21 | 21.59 | 4.31 | 0.05 |
| Fixed Asset Turnover | 0.04 | 0.03 | 0.04 | 0.09 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 |
| Cash Conversion Cycle | 2302.25 | 2021.13 | 220.95 | 27.68 | -528.08 |
| Days of Sales Outstanding | 2249.97 | 323.25 | 213.08 | 13.13 | 282.05 |
| Days of Inventory Outstanding | 52.28 | 1697.87 | 16.90 | 84.69 | 7469.15 |
| Days of Payables Outstanding | 0.00 | 0.00 | 9.04 | 70.14 | 8279.27 |
| Operating Cycle | 2302.25 | 2021.13 | 229.99 | 97.82 | 7751.19 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.39 | -2.11 | -1.91 | -1.23 | -1.07 |
| Free Cash Flow Per Share | -2.60 | -2.39 | -1.97 | -1.53 | -1.24 |
| Dividend Paid and CapEx Coverage Ratio | -11.37 | -7.66 | -31.81 | -3.96 | -6.13 |
| Capital Expenditure Coverage Ratio | -11.37 | -7.66 | -31.81 | -3.96 | -6.13 |
| Operating Cash Flow Coverage Ratio | -62.99 | -26.89 | -34.90 | -7.69 | -1.42 |
| Operating Cash Flow to Sales Ratio | -110.09 | -104.82 | -66.29 | -11.37 | -228.74 |
| Free Cash Flow Yield | -3.01% | -3.93% | -7.90% | -5.06% | -2.24% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -29.93 | -24.76 | -12.17 | -23.88 | -46.96 |
| Price-to-Sales (P/S) Ratio | 3972.65 | 3018.33 | 865.55 | 281.45 | 11877.70 |
| Price-to-Book (P/B) Ratio | 5.49 | 7.78 | 5.21 | 4.41 | 5.13 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -33.17 | -25.47 | -12.66 | -19.76 | -44.64 |
| Price-to-Operating Cash Flow Ratio | -36.08 | -28.80 | -13.06 | -24.75 | -51.93 |
| Price-to-Earnings Growth (PEG) Ratio | -1.75 | -1.24 | -0.20 | -3.13 | 1.67 |
| Enterprise Value Multiple | -27.57 | -26.00 | -11.96 | -20.94 | -45.51 |
| Enterprise Value | 2.34B | 1.66B | 553.08M | 631.96M | 892.80M |
| EV to EBITDA | -27.57 | -26.00 | -11.96 | -20.94 | -45.51 |
| EV to Sales | 3314.03 | 2705.03 | 759.72 | 234.32 | 10145.45 |
| EV to Free Cash Flow | -27.67 | -22.83 | -11.11 | -16.45 | -38.13 |
| EV to Operating Cash Flow | -30.10 | -25.81 | -11.46 | -20.61 | -44.35 |
| Tangible Book Value Per Share | 15.69 | 7.82 | 4.79 | 6.88 | 10.81 |
| Shareholders’ Equity Per Share | 15.69 | 7.82 | 4.79 | 6.88 | 10.81 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.09 | 0.20 | 0.18 |
| Revenue Per Share | 0.02 | 0.02 | 0.03 | 0.11 | 0.00 |
| Net Income Per Share | -2.88 | -2.46 | -2.05 | -1.27 | -1.18 |
| Tax Burden | 1.00 | 1.00 | 0.91 | 0.80 | 0.82 |
| Interest Burden | 0.98 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 83.96 | 87.48 | 51.48 | 11.73 | 241.08 |
| SG&A to Revenue | 36.69 | 37.71 | 20.77 | 4.83 | 81.10 |
| Stock-Based Compensation to Revenue | 9.60 | 0.53 | 0.88 | 0.00 | 0.00 |
| Income Quality | 0.83 | 0.86 | 0.85 | 0.77 | 0.74 |
Currency in TWD
